In-silico Phase 4 program using digital twins
by Pierre Etienne
in Actu-Real Blog
Typically, manufacturers start to seriously think about how to set an asking price for a new treatment (drug or biologic or combination) around the time of the submission of their P3 registration data. At that point they have little real evidence of the benefits and risks of the new treatment, or the consequences of the […]